宝贝很精致,看着还不错!
Zhou Jun, CEO of Berry Oncology, a leading Chinese company in genetic testing and early screening of tumors, said a root cause for investors' sustained enthusiasm for early cancer screening is that although various innovative therapies have been made available in the market in recent years for cancer, once the disease progresses to the middle and late stages, the benefits from drugs will become very limited, while related expenditures at both the individual level and the society level can be huge.
贝瑞基因首席执行官周珺表示,投资者对早癌筛查行业投资热情持续高涨的一个根本原因是,尽管近年来市场上有各种创新疗法治疗癌症,但一旦癌症发展到中晚期,药物的作用将变得非常有限,而个人和社会层面的相关支出可能会非常巨大